On June 27, 2025, HC Wainwright & Co. analyst Yi Chen reiterated a "Buy" rating on Lipocine (LPCN, Financial), consistently maintaining the price target at $8.00 USD. The ongoing support from the analyst signals confidence in Lipocine's market potential.
The decision to maintain the stock's "Buy" rating and price target of $8.00 USD indicates that HC Wainwright & Co. continues to see value in Lipocine's stock (LPCN, Financial). This is consistent with the prior analysis, reflecting stability in the company's projected financial performance.
Lipocine (LPCN, Financial) remains a focus for investors as HC Wainwright & Co.'s retained price target and rating provide reassurance for those holding positions or considering entry into the stock. Investors will keep an eye on future updates and performance metrics as they align with this analytical outlook.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Lipocine Inc (LPCN, Financial) is $7.38 with a high estimate of $8.00 and a low estimate of $6.75. The average target implies an upside of 129.04% from the current price of $3.22. More detailed estimate data can be found on the Lipocine Inc (LPCN) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Lipocine Inc's (LPCN, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
